Prostaglandin Analogs for Glaucoma
Master prostaglandin analogs for glaucoma: mechanism, agents, adverse effects and board-focused clinical pearls.
For many patients with primary open-angle glaucoma, the usual first-line topical medication class is:
Prostaglandin Analogs in 30 Seconds
Prostaglandin analogs are first-line topical glaucoma medications that act as FP receptor agonists to increase uveoscleral outflow and lower IOP by 20 to 35%. Latanoprost is the prototype agent. Most are dosed once daily, typically in the evening.
Mechanism and IOP Lowering
FP receptor agonism remodels the extracellular matrix within the ciliary muscle, reducing resistance and increasing uveoscleral outflow. These drugs also increase some trabecular outflow. They are the most effective topical class, lowering IOP 20 to 35%. Most are administered once daily, typically in the evening, because maximal IOP reduction occurs several hours after instillation. Importantly, more frequent than once-daily dosing can paradoxically reduce efficacy, so the once-daily schedule should be maintained.
Agents in This Class
- Latanoprost (Xalatan): prototype once-daily FP agonist. Exam relevance: the reference first-line prostaglandin analog.
- Bimatoprost (Lumigan): FP agonist with additional prostamide activity, also FDA-approved for cosmetic eyelash growth (Latisse). Exam relevance: often associated with hyperemia and eyelash changes.
- Travoprost (Travatan Z): once-daily FP agonist. Exam relevance: effective alternative to latanoprost.
- Tafluprost: preservative-free formulation for patients with ocular surface disease or preservative intolerance. Exam relevance: consider when preservatives limit therapy.
- Latanoprostene bunod: FP agonist that also releases nitric oxide, adding trabecular outflow benefit. Exam relevance: dual mechanism targets both uveoscleral and trabecular pathways.
Side Effects (High-Yield)
- Conjunctival hyperemia: most common adverse effect, usually mild. Exam relevance: expected local reaction, not a reason to stop therapy in most patients.
- Iris pigmentation: increased melanin synthesis in existing stromal melanocytes, irreversible, more common in hazel eyes. Exam relevance: not melanocyte proliferation, not precancerous.
- Periorbital changes: deepened upper lid sulcus, ptosis, enophthalmos-like appearance and periorbital fat atrophy define prostaglandin-associated periorbitopathy. Exam relevance: generally reversible after stopping the drug.
- Eyelash changes: hypertrichosis with increased length, thickness and pigmentation. Exam relevance: cosmetic effect, basis for bimatoprost's cosmetic approval.
- Uveitis/CME: use cautiously in active uveitis or aphakic/pseudophakic eyes with disrupted posterior capsule. Exam relevance: CME risk in these specific situations.
- Herpetic keratitis: may reactivate. Exam relevance: use with caution in patients with prior ocular herpes.
4 Facts Exams Always Ask
- First-line IOP-lowering agent, primarily increasing uveoscleral outflow through FP receptor agonism with 20 to 35% IOP reduction.
- Irreversible iris darkening results from increased melanin synthesis in existing stromal melanocytes, not melanocyte proliferation, so it is not precancerous.
- Prostaglandin-associated periorbitopathy includes deepened upper lid sulcus, ptosis, enophthalmos-like appearance and periorbital fat atrophy.
- Relatively contraindicated in active uveitis and aphakic or pseudophakic eyes with disrupted posterior capsule because of CME risk.
The Classic Trap
Iris color change reflects increased melanin in existing stromal melanocytes, not new melanocyte growth, so it is not precancerous. A second trap is that prostaglandins are relatively contraindicated in active uveitis and aphakia with posterior-capsule disruption because of CME risk, not because they cause glaucoma. Remember that once-daily dosing is essential since more frequent administration can paradoxically reduce IOP-lowering efficacy.
Clinical Pearl
Prostaglandin analogs are first-line because once-daily dosing, 20 to 35% IOP reduction and minimal systemic adverse effects promote efficacy and adherence. Periorbital changes are cosmetically significant but generally reversible after discontinuation, whereas iris darkening is irreversible. The distinction between reversible periorbital effects and irreversible iris pigmentation is a classic board pairing.
Checkpoint 1
A patient using bimatoprost for glaucoma develops progressive darkening of the iris. What is the underlying mechanism for this adverse effect?
Checkpoint 2
Which medication class commonly causes conjunctival hyperemia and iris pigmentation changes as notable ocular side effects?
A 62-year-old patient with primary open-angle glaucoma has used latanoprost nightly for 18 months. IOP is well controlled, but the patient notices darker hazel irides, longer eyelashes and a deeper upper lid sulcus. The patient asks whether these findings suggest cancer and whether they will resolve if latanoprost is stopped.
A patient on latanoprost for 18 months develops darker hazel irides. Is this finding reversible, and does it indicate a precancerous change?
Sources & Publisher Info
Last clinically reviewed: August 9, 2026
References
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 10: Glaucoma.
- American Academy of Ophthalmology. EyeWiki: Glaucoma Medical Therapy.
- American Academy of Ophthalmology. EyeWiki: Prostaglandin-Associated Periorbitopathy.
- American Academy of Ophthalmology. EyeWiki: Cystoid Macular Edema.
More Pharmacology topics
Ready for the real thing?
Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.
Practice Pharmacology →